Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek DHA powder

This article was originally published in The Tan Sheet

Executive Summary

Martek is launching a new powdered form of the omega-3 fatty DHA acid for use in food and beverage products, the firm announces March 20. The company's vegetarian form of DHA (docosahexaenoic acid) powder contains higher amounts of DHA than fish oil powders, "leading to easier food formulation because less powder is needed to achieve desired DHA levels," the Columbia, Md.-based firm states. The new algae-derived DHA powder is available in 10% and 17% DHA concentrations. The introduction of DHA as a food and beverage ingredient follows the business plan outlined by the firm in January, allowing Martek to expand the DHA market beyond infants and effectively make DHA a "lifetime product" (1"The Tan Sheet" Jan. 16, 2006, p. 12)...

You may also be interested in...



Martek Reaches Beyond Infant Formula To Grab Perinatal, Food Markets

Martek Biosciences is supplying DHA for Mission Pharmacal's upcoming Rx perinatal dietary supplement Citracal + DHA, the firm announced during a presentation to investors

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

Topics

UsernamePublicRestriction

Register

PS099221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel